inclusion criteria: * participant must be healthy, in the investigator's clinical judgment, as confirmed by medical history, physical examination, and vital signs performed at screening. participants may have underlying illnesses, as long as the symptoms and signs are medically controlled * participant either received complete primary vaccination with an authorized/licensed coronavirus disease-2019 (covid-19) vaccine (completed greater than or equal to \[\>=\] 6 months prior to the last vaccination received against covid-19) or is covid-19 vaccine-naive * all participants who were born female and are of childbearing potential must: a. have a negative highly sensitive urine pregnancy test at screening, b. have a negative highly sensitive urine pregnancy test on the day of vaccination prior to each study vaccine administration * participant agrees to not donate or receive bone marrow, blood, and blood products from the administration of the study vaccine until 3 months after receiving the study vaccines * participant must be willing to provide verifiable identification to be contacted and to contact the investigator during the study

inclusion criteria: * participant must be healthy, in the investigator's clinical judgment, as confirmed by medical history, physical examination, and vital signs performed at screening. participants may have underlying illnesses, as long as the symptoms and signs are medically controlled * participant either received complete primary vaccination with an authorized/licensed coronavirus disease-2019 (covid-19) vaccine (completed greater than or equal to \[\>=\] 6 months prior to the last vaccination received against covid-19) or is covid-19 vaccine-naive * all participants who were born female and are of childbearing potential must: a. have a negative highly sensitive urine pregnancy test at screening, b. have a negative highly sensitive urine pregnancy test on the day of vaccination prior to each study vaccine administration * participant agrees to not donate or receive bone marrow, blood, and blood products from the administration of the study vaccine until 3 months after receiving the study vaccines * participant must be willing to provide verifiable identification to be contacted and to contact the investigator during the study

inclusion criteria: participant must be healthy, in the investigator's clinical judgment, as confirmed by medical history, physical examination, and vital signs performed at screening. participants may have underlying illnesses, as long as the symptoms and signs are medically controlled participant either received complete primary vaccination with an authorized/licensed coronavirus disease-2019 (covid-19) vaccine (completed greater than or equal to [>=] 6 months prior to the last vaccination received against covid-19) or is covid-19 vaccine-naive all participants who were born female and are of childbearing potential must: a. have a negative highly sensitive urine pregnancy test at screening, b. have a negative highly sensitive urine pregnancy test on the day of vaccination prior to each study vaccine administration participant agrees to not donate or receive bone marrow, blood, and blood products from the administration of the study vaccine until 3 months after receiving the study vaccines participant must be willing to provide verifiable identification to be contacted and to contact the investigator during the study

inclusion criteria: participant must be healthy, in the investigator's clinical judgment, as confirmed by medical history, physical examination, and vital signs performed at screening. participants may have underlying illnesses, as long as the symptoms and signs are medically controlled participant either received complete primary vaccination with an authorized/licensed coronavirus disease-2019 (covid-19) vaccine (completed greater than or equal to [>=] 6 months prior to the last vaccination received against covid-19) or is covid-19 vaccine-naive all participants who were born female and are of childbearing potential must: a. have a negative highly sensitive urine pregnancy test at screening, b. have a negative highly sensitive urine pregnancy test on the day of vaccination prior to each study vaccine administration participant agrees to not donate or receive bone marrow, blood, and blood products from the administration of the study vaccine until 3 months after receiving the study vaccines participant must be willing to provide verifiable identification to be contacted and to contact the investigator during the study

None

None

inclusion criteria: participant must be healthy, in the investigator's clinical judgment, as confirmed by medical history, physical examination, and vital signs performed at screening. participants may have underlying illnesses, as long as the symptoms and signs are medically controlled participant either received complete primary vaccination with an authorized/licensed coronavirus disease-2019 (covid-19) vaccine (completed greater than or equal to [>=] 6 months prior to the last vaccination received against covid-19) or is covid-19 vaccine-naive all participants who were born female and are of childbearing potential must: a. have a negative highly sensitive urine pregnancy test at screening, b. have a negative highly sensitive urine pregnancy test on the day of vaccination prior to each study vaccine administration participant agrees to not donate or receive bone marrow, blood, and blood products from the administration of the study vaccine until 3 months after receiving the study vaccines participant must be willing to provide verifiable identification to be contacted and to contact the investigator during the study

inclusion criteria: participant must be healthy, in the investigator's clinical judgment, as confirmed by medical history, physical examination, and vital signs performed at screening. participants may have underlying illnesses, as long as the symptoms and signs are medically controlled participant either received complete primary vaccination with an authorized/licensed coronavirus disease-2019 (covid-19) vaccine (completed greater than or equal to [>=] 6 months prior to the last vaccination received against covid-19) or is covid-19 vaccine-naive all participants who were born female and are of childbearing potential must: a. have a negative highly sensitive urine pregnancy test at screening, b. have a negative highly sensitive urine pregnancy test on the day of vaccination prior to each study vaccine administration participant agrees to not donate or receive bone marrow, blood, and blood products from the administration of the study vaccine until 3 months after receiving the study vaccines participant must be willing to provide verifiable identification to be contacted and to contact the investigator during the study

inclusion criteria: - participant must be healthy, in the investigator's clinical judgment, as confirmed by medical history, physical examination, and vital signs performed at screening. participants may have underlying illnesses, as long as the symptoms and signs are medically controlled - participant either received complete primary vaccination with an authorized/licensed coronavirus disease-2019 (covid-19) vaccine (completed greater than or equal to [>=] 6 months prior to first study vaccination) or is covid-19 vaccine-naive - all participants who were born female and are of childbearing potential must: a. have a negative highly sensitive urine pregnancy test at screening, b. have a negative highly sensitive urine pregnancy test on the day of each study vaccine administration - participant agrees to not donate or receive bone marrow, blood, and blood products from the administration of the study vaccine until 3 months after receiving the study vaccines - participant must be willing to provide verifiable identification to be contacted and to contact the investigator during the study

inclusion criteria: - participant must be healthy, in the investigator's clinical judgment, as confirmed by medical history, physical examination, and vital signs performed at screening. participants may have underlying illnesses, as long as the symptoms and signs are medically controlled - participant either received complete primary vaccination with an authorized/licensed coronavirus disease-2019 (covid-19) vaccine (completed greater than or equal to [>=] 6 months prior to first study vaccination) or is covid-19 vaccine-naive - all participants who were born female and are of childbearing potential must: a. have a negative highly sensitive urine pregnancy test at screening, b. have a negative highly sensitive urine pregnancy test on the day of each study vaccine administration - participant agrees to not donate or receive bone marrow, blood, and blood products from the administration of the study vaccine until 3 months after receiving the study vaccines - participant must be willing to provide verifiable identification to be contacted and to contact the investigator during the study